Nicholas Investment Partners, LP Biomarin Pharmaceutical Inc Transaction History

Nicholas Investment Partners, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$80.93 - $108.63 $9.66 Million - $13 Million	119,372 New	119,372 $12.4 Million
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $6.09 Million - $7.39 Million	-81,530 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$72.61 - $90.2 $1.07 Million - $1.33 Million	-14,746 Reduced 15.32%	81,530 $7.15 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $6.92 Million - $12.6 Million	96,276 New	96,276 $7.33 Million
Q2 2020 Aug 12, 2020	SELL	$79.55 - $124.22 $2.09 Million - $3.27 Million	-26,302 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$71.37 - $96.85 $1.88 Million - $2.55 Million	26,302 New	26,302 $2.22 Million
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $1.33 Million - $1.74 Million	-17,548 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $1.59 Million - $1.9 Million	-20,494 Reduced 53.87%	17,548 $1.42 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $17,201 - $20,262	213 Added 0.56%	38,042 $3.39 Million
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $3.05 Million - $3.59 Million	37,829	37,829 $3.52 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.